This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winding, B. Articles by Delaissé, J.-M. Search for Related Content PubMed PubMed Citation Articles by Winding, B. Articles by Delaissé, J.-M.

Synthetic Matrix Metalloproteinase Inhibitors Inhibit Growth of Established Breast Cancer Osteolytic Lesions and Prolong Survival in Mice

Nordic Bioscience and Center for Clinical and Basic Research, Herlev/Ballerup, DK-2730 Herlev, Denmark [B. W., R. N. A., H. M., P. H. A., T. L. A., A. M. H., N. T. F., J. M. D.], and Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark [C. H. H., N. B.]

Purpose: Breast cancer frequently leads to incurable bone metastasis.Essential requirements for the development of bone metastasis are cell-cell and cell-matrix interactions, release of bioactive growth factors and cytokines, and removal of large amounts of bone matrix. Matrix metalloproteinases (MMPs) play an important role in all of these processes, but the possibility of using synthetic MMP inhibitors to decrease bone metastasis has received little attention.

Experimental Design: In the present study, we tested two general MMP inhibitors, BB-94 and GM6001, in a mouse model of breast cancer-induced bone metastasis.

Results: In a simulation of intervention therapy, mice were inoculated with breast cancer cells, and at the time of diagnosis of osteolytic lesions, the mice were treated for 10 or 15 consecutive days with BB-94 or GM6001, respectively. Both inhibitors reduced the growth of osteolytic lesions by >55% compared with control mice. Next, we simulated prevention therapy by initiating treatment with GM6001 at time of inoculation with cancer cells or 3 days earlier. Assessment of osteolytic lesions 28 days after inoculation showed that, in both cases, the treatment reduced the size of the osteolytic lesions by 60%, compared with that of control mice. Importantly, MMP inhibition also resulted in extension of symptom-free survival in the mice, whether the treatment was initiated at the time of diagnosis of osteolytic lesions or of cancer cell inoculation.

Conclusions: The present study suggests the potential of synthetic MMP inhibitors as intervention or prevention treatments of breast cancer-induced osteolysis.

This article has been cited by other articles:

				K. Almholt, A. Juncker-Jensen, O. D. Laerum, K. Dano, M. Johnsen, L. R. Lund, and J. Romer Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model Mol. Cancer Ther., September 1, 2008; 7(9): 2758 - 2767. [Abstract] [Full Text] [PDF]

				R. D. Bonfil, Z. Dong, J. C. Trindade Filho, A. Sabbota, P. Osenkowski, S. Nabha, H. Yamamoto, S. R. Chinni, H. Zhao, S. Mobashery, et al. Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase: A Pivotal Role in Bone Response and Intraosseous Tumor Growth Am. J. Pathol., June 1, 2007; 170(6): 2100 - 2111. [Abstract] [Full Text] [PDF]

				M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]

				Z. Dong, R. D. Bonfil, S. Chinni, X. Deng, J. C. Trindade Filho, M. Bernardo, U. Vaishampayan, M. Che, B. F. Sloane, S. Sheng, et al. Matrix Metalloproteinase Activity and Osteoclasts in Experimental Prostate Cancer Bone Metastasis Tissue Am. J. Pathol., April 1, 2005; 166(4): 1173 - 1186. [Abstract] [Full Text] [PDF]

				X. Zhang, M. Cheng, and S. K. Chintala Kainic Acid-Mediated Upregulation of Matrix Metalloproteinase-9 Promotes Retinal Degeneration Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2374 - 2383. [Abstract] [Full Text] [PDF]

				L.S. Holliday, A. Vakani, L. Archer, and C. Dolce Effects of Matrix Metalloproteinase Inhibitors on Bone Resorption and Orthodontic Tooth Movement Journal of Dental Research, September 1, 2003; 82(9): 687 - 691. [Abstract] [Full Text] [PDF]

				M. L. Cher, H. R. Biliran Jr., S. Bhagat, Y. Meng, M. Che, J. Lockett, J. Abrams, R. Fridman, M. Zachareas, and S. Sheng Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis PNAS, June 24, 2003; 100(13): 7847 - 7852. [Abstract] [Full Text] [PDF]

				G. L. Barnes, A. Javed, S. M. Waller, M. H. Kamal, K. E. Hebert, M. Q. Hassan, A. Bellahcene, A. J. van Wijnen, M. F. Young, J. B. Lian, et al. Osteoblast-related Transcription Factors Runx2 (Cbfa1/AML3) and MSX2 Mediate the Expression of Bone Sialoprotein in Human Metastatic Breast Cancer Cells Cancer Res., May 15, 2003; 63(10): 2631 - 2637. [Abstract] [Full Text] [PDF]